In a third trial (Rocha et al. 2015) the early MetS group had a significant reduction in CD34+/KDR+ and CD133+/CD34+/KDR+ EPC levels after a bout of MICON compared with their age-matched healthy control group. Here, CD34 is linked to metabolic syndrome.